Article Versions Notes

Cheng X, Zhao G, Dong A, He Z, Wang J, Jiang B, Wang B, Wang M, Huai X, Zhang S, et al. A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of Age. Vaccines. 2023; 11(5):999. https://doi.org/10.3390/vaccines11050999

Cheng, Xin, Gan Zhao, Aihua Dong, Zhonghuai He, Jiarong Wang, Brian Jiang, Bo Wang, Miaomiao Wang, Xuefen Huai, Shijie Zhang, and et al. 2023. "A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of Age" Vaccines 11, no. 5: 999. https://doi.org/10.3390/vaccines11050999

Cheng, X., Zhao, G., Dong, A., He, Z., Wang, J., Jiang, B., Wang, B., Wang, M., Huai, X., Zhang, S., Feng, S., Qin, H., & Wang, B. (2023). A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of Age. Vaccines, 11(5), 999. https://doi.org/10.3390/vaccines11050999